IDE034
Source
AACR 2026 Munoz et al.
Publications
ADC+DDR Combos
Combining targeted DNA damage with repair pathway inhibition to create synthetic lethality in cancer cells.
IDE849
Source
ESMO 2026 Liu et al.
SHR-4849 (IDE849), an ADC targeting delta-like ligand 3 (DLL3), in relapsed small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs): long-term results from the Phase 1 study
Read more (opens in a new tab)IDE161
Source
IASLC WCLC 2025 Maskey et al.
Dual PARG-TOP1 inhibition exacerbates DNA-protein crosslinks and replication stress: A promising strategy for enhancing Top1i-ADC efficacy
Read more (opens in a new tab)IDE161
Source
EORTC-NCI-AACR 2024 Munoz et al.
IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets solid tumors with replication stress and DNA repair vulnerabilities
Read more (opens in a new tab)MTAP Pathway
Exploiting the dual metabolic vulnerabilities created by MTAP loss through a differentiated combination approach designed to drive deep and durable tumor responses.
IDE397 and IDE892
Source
AACR 2026 Rao et al.
IDE892 is a highly potent and selective PRMT5 inhibitor, with MTA-positive and SAM-negative cooperativity, optimized for development in MTAP-deleted cancers in combination with the allosteric MAT2A inhibitor IDE397
Read more (opens in a new tab)IDE397 and IDE892
Source
AACR 2025 Aubi et al.
The impact of metabolite kinetics on dysregulation of essential enzymes in cancers with MTAP deficiencies
Read more (opens in a new tab)IDE397 and IDE892
Source
EORTC-NCI-AACR 2024 Garbett et al.
